Rhenman Healthcare Equity L/S ranked as the best fund in EuroHedge
Since its inception in June, 2009, the Fund has increased in value by over 78%.
The sector fund Rhenman Healthcare Equity L/S, which invests in listed companies primarily in pharmaceuticals, medical technology, biotechnology and healthcare, has been ranked number 1 based on average annual return among 44 global funds (with more than three years track record) in the latest issue of EuroHedge, which is one of the leading publications for hedge funds in Europe.
The ranking is based on the funds' performance, and for Rhenman Healthcare Equity L/S, the annualized compound return is +16.64% since the Fund’s inception on 22 June, 2009. This makes it the best performing fund, more than 0.5 percentage points better than the second-ranked fund.
Based on fund development over the past twelve months Rhenman Healthcare Equity L/S is also in first place, with an increase of +23.69%, over 8 percentage points better than the next-best fund. Since fund inception on 22 June, 2009, the Fund has increased in value by as much as +78.11%.
"It is gratifying that our fund is ranked as the best performing fund in Europe among so many large, established European hedge fund managers. The healthcare sector makes up 10 percent of the world's total market capitalization, so the Fund has many investment opportunities to choose from, and the management team has handled this admirably,” says Carl Grevelius, Founding Partner and Head of Marketing.
"We believe that the healthcare sector in the future will benefit from an ageing population, increasing wealth in developing countries and the continued development of new medical products and technologies. Many investors have reached the same conclusion, both in Sweden and internationally, which has resulted in relatively large inflows of funds. The company's assets under management now amount to over 1 billion kronor. "
Four years ago the investment company Rhenman & Partners Asset Management created a highly distinguished scientific council, with Professor Bertil Hållsten as chairman. The company's board also includes Professor Hans Wigzell, former Principal of the Karolinska Institute and former chairman of the Karolinska Institute's Nobel Prize Committee, and Håkan Åström, former CEO of Kabi Pharmacia.
Rhenman Healthcare Equity L/S offers monthly liquidity and is aimed at both private investors and at institutions. Rhenman & Partners collaborates with SEB, who act as central administration agent and promoter of the fund.
For further information, please contact:
Carl Grevelius, Head of Sales & Marketing / Founding Partner
Phone: +46 8 459 88 83
Email: carl@rhepa.com
Notes to editors
About Rhenman & Partners
Rhenman & Partners Asset Management is a Stockholm-based niche player focusing on the healthcare sector. The company's assets under management amount to over 1 billion kronor. Rhenman & Partners was founded in 2008 by a group of individuals with extensive experience of the asset management sector, as well as an unrivaled track record in the healthcare sector. The Rhenman Healthcare Equity L/S fund is unique in that it is supported by a scientific council composed of eminent professors who have a wide network of scientists and experts at several recognized institutions worldwide, including the Karolinska Institute. For more information, please visit www.rhepa.com
Rhenman Healthcare Equity L/S performance (EUR, net of fees) - An absolute return fund
- Since inception (June 2009) + 78%
- 2013 YTD (Feb) + 12%
- 2012 + 18%
- 2011 + 10%
- 2010 + 8%
- 2009 + 13%
